Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: n/a - observational study Clear all
Completed Phase 3 Interventional Results available

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

NCT00033293
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
Other · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 8 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 30, 2026, 4:48 PM EDT
Enrolling by invitation No phase listed Observational

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

NCT04266093
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix, Hematologic Malignacies
Interventions
GeneTherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418
View directory record Official record
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Los Angeles, California • San Marcos, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational Results available

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

NCT03563183
View directory record Official record
Conditions
Herpes Zoster
Interventions
Encoding of data collected in Zoster 006 and Zoster 022 studies
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
26,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Mesa, Arizona • Phoenix, Arizona • Spring Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia

NCT02003612
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not applicable - observational study
Other
Lead sponsor
Amgen
Industry
Eligibility
15 Years and older
Enrollment
2,373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 30, 2026, 4:48 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Continuous N-of-1 Computational Feasibility Study of a Whole Genome Sequence

NCT07462234
View directory record Official record
Conditions
Computational Modeling of Individual Metabolic Pathways
Interventions
Not listed
Lead sponsor
Bioactify LLC
Other
Eligibility
Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Wappingers Falls, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

NCT07787117
View directory record Official record
Conditions
Asthma
Interventions
None (observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
Not listed
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
2 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

NCT01033240
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Liver Cancer, Hepatic Cancer, Liver Neoplasms
Interventions
CS-1008 2 mg/kg, Sorafenib, CS-1008 6/2 mg/kg, CS-1008 6/6 mg/kg, CS-1008 4 mg/kg, CS-1008 6 mg/kg
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

NCT04510220
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, [F-18]PBR06
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study

NCT06364865
View directory record Official record
Conditions
Gall Bladder Disease, Bile Duct Diseases, Acute Cholecystitis, Kidney, Liver, Appendix, Spleen Disease, Prostate
Interventions
laparoscopic procedure
Device
Lead sponsor
Teleflex
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • New Hyde Park, New York • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

Muscle Recovery After Critical Illness

NCT05537298
View directory record Official record
Conditions
ICU Acquired Weakness, Post Intensive Care Unit Syndrome, Muscle Weakness, Critical Illness
Interventions
Not listed
Lead sponsor
Esther Dupont-Versteegden
Other
Eligibility
18 Years and older · Male only
Enrollment
209 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Lexington, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934
View directory record Official record
Conditions
ATTR Amyloidosis
Interventions
no intervention
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
52,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

NCT03908632
View directory record Official record
Conditions
Coccidioidomycosis, Pneumonia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational Results available

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

NCT02443571
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Fluciclovine (18F)
Radiation
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 30, 2026, 4:48 PM EDT
Terminated No phase listed Observational

Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

NCT02306135
View directory record Official record
Conditions
Cancer
Interventions
n/a- this is an observational study
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational Results available

Developing a Down Syndrome Health Instrument

NCT04631237
View directory record Official record
Conditions
Down Syndrome, Health, Subjective
Interventions
Observational, no intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.

NCT03349515
View directory record Official record
Conditions
Strabismus
Interventions
Provodine-Iodine Solution, Group B will receive three drops in each eye of ophthalmic balanced salt solution.
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
1 Year to 17 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational Results available

Medtronic Signia SDR Product Surveillance Registry

NCT05095935
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Surgical Procedures, Operative
Interventions
N/A observational registry
Other
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 30, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 30, 2026, 4:48 PM EDT
Completed No phase listed Observational

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

NCT04014764
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm
Interventions
This is a non-interventional study
Other
Lead sponsor
Notable Labs
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Bakersfield, California • San Luis Obispo, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 30, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

NCT06429280
View directory record Official record
Conditions
Amblyopia
Interventions
N/A this is an observational study of Standard of Care
Device
Lead sponsor
Luminopia
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
San Ramon, California • Santa Barbara, California • Crestview, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 4:48 PM EDT